stockportfolio.pro
Artivion, Inc. (AORT)
Healthcare · Medical Devices · NYSE
Artivion, Inc. revenue & earnings — last 10 fiscal years
| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $180.38M | $189.70M | $262.84M | $276.22M | $253.23M | $298.84M | $313.79M | $354.00M | $388.54M | $441.33M |
| Gross profit | $118.90M | $128.64M | $172.98M | $183.01M | $167.78M | $197.51M | $202.52M | $229.18M | $248.78M | $284.23M |
| Net income | $10.78M | $3.70M | $-2.84M | $1.72M | $-16.68M | $-14.83M | $-19.19M | $-30.69M | $-13.36M | $9.77M |
| Net margin | 6.0% | 2.0% | -1.1% | 0.6% | -6.6% | -5.0% | -6.1% | -8.7% | -3.4% | 2.2% |
Source: Artivion, Inc. SEC filings (10-K). 17 years of history available in the interactive view.
Explore 17 years of Artivion, Inc. financials — interactive
Full income statement, balance sheet and cash flow with CAGR and trend on every row, 48 quarters, valuation ratios, plain-English health checks, and Ask — our SEC-grounded research assistant.
Open the interactive view — freeOr start a 7-day free trial to track AORT in your portfolio →
About Artivion, Inc.
Artivion, Inc. manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company offers On-X prosthetic aortic and mitral heart valves; On-X ascending aortic prosthesis; CarbonAid CO2 diffusion catheters; Chord-X ePTFE sutures; pyrolytic carbon coating services; E-vita Open NEO, a hybrid stent graft; Arcevo, an LSA hybrid stent graft system; AMDS hybrid prosthesis; and NEXUS ONE, an endovascular stent graft system. It also provides NEXUS DUO, an aortic arch system; NEXUS TRE, a custom-made three branch graft; E-vita thoracic 3G, a stent graft system; E-xtra Design Engineering, a range of stent graft systems for the treatment of aortic vascular diseases, such as TAAA and Artivex; E-nside, a multibranch stent graft system; E-tegra, an AAA stent graft system; E-ventus BX and Tuva BX balloon-expandable peripheral stent grafts; and E-liac, a stent graft used to treat aneurysmal iliac arteries. In addition, the company offers synthetic vascular grafts that are used in open aortic and peripheral vascular surgical procedures; BioGlue, a surgical sealant; CryoValve SG pulmonary heart valve; CryoPatch SG pulmonary cardiac patch; SynerGraft, a decellularization technology; vascular preservation services; and PhotoFix, a bovine pericardial patch fixated. It markets its products and preservation services primarily to physicians through a direct sales team to hospitals and other healthcare facilities. The company was formerly known as CryoLife, Inc. and changed its name to Artivion, Inc. in January 2022. Artivion, Inc. was incorporated in 1984 and is headquartered in Kennesaw, Georgia.
Artivion, Inc. — frequently asked questions
What is Artivion, Inc.'s revenue?
Artivion, Inc. (AORT) reported revenue of $441.33M for fiscal year 2025, up 13.6% from the prior year, according to its SEC filings.
Is Artivion, Inc. profitable?
Yes. AORT earned net income of $9.77M in fiscal 2025, a net margin of 2.2%.
What is AORT's P/E ratio?
Artivion, Inc. trades at a price-to-earnings ratio of about 82.3 based on the latest data in our nightly-refreshed cache.
How fast is Artivion, Inc. growing?
AORT's revenue grew at roughly 11.8% per year over the last five fiscal years (compound annual growth rate), computed from SEC-filed statements.
Where does this data come from?
All figures are computed from Artivion, Inc.'s official SEC filings (10-K and 10-Q), covering 17 years of history, refreshed nightly. stockportfolio.pro does not provide investment advice.